Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk:: a prospective study
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk:: a prospective study
复制标题
DOI：
10.1093/jnci/92.23.1910
复制
发表时间：
2000-12-06
期刊：
影响因子：
--
通讯作者：
Kaaks, R
中科院分区：
文献类型：
--
作者：
Stattin, P;Bylund, A;Kaaks, R
背景：最近的研究表明，血浆中胰岛素样生长因子- i （IGF-I）水平升高的男性患前列腺癌的风险可能增加。此外，igf结合蛋白（igfbp）和胰岛素可以调节IGF-I的活性。在本研究中，我们试图确定IGF-I、igfbp -1、-2和-3和胰岛素作为前列腺癌可能的病因的作用。方法：我们在瑞典北部健康与疾病队列研究中进行了巢式病例对照研究。我们测量了149名在采血后1个月至10个月内被诊断为前列腺癌的男性和298名对照男性的血浆样本中igf -1、IGFBP-1、IGFBP-2、IGFBP-3和胰岛素的水平。所有的统计检验都是双侧的。结果：病例组的igf - 1平均水平显著高于对照组（229 ng/mL， 95%可信区间[CT] = 218-240 ng/mL]和214 ng/mL [95% CI = 208-221 ng/mL], P = 0.02）和IGFBP-3 （2611 ng/mL [95% CI = 2518-2704 ng/mL]和2498 ng/mL [95% CI = 2437-2560 ng/mL], P = 0.04）。条件逻辑回归分析显示，随着igf - 1 （P-for趋势= 0.02）和IGFBP-3 （P-for趋势= 0.03）水平的升高，前列腺癌风险增加。在采集血液时年龄小于59岁的受试者中，与igf - 1升高相关的风险较高（P-for趋势= 0.01），而与IGFBP-3升高相关的风险较低（P-for趋势= 0.44）。前列腺癌风险与IGFBP-1、IGFBP-2或胰岛素水平无关。结论：血浆IGF-I升高的男性患前列腺癌的风险增加，在本研究中，这种关联在年轻男性中尤为明显，提示循环IGF-I可能专门参与前列腺癌的早期发病机制。
Background: Recent studies have suggested that men with elevated plasma levels of insulin-like growth factor-I (IGF-I) may have an increased risk of prostate cancer. Furthermore, IGF-binding proteins (IGFBPs) and insulin can modulate the activity of IGF-I, In this study, we sought to determine the role of IGF-I as well as IGFBPs-1, -2, and -3 and insulin as possible etiologic factors for prostate cancer. Methods: We conducted a nested case-control study within the Northern Sweden Health and Disease Cohort Study. We measured levels of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, and insulin in plasma samples from 149 men who had a diagnosis of prostate cancer between I month and 10 Sears after blood collection and among 298 control men. All statistical tests are two-sided. Results: Case subjects had statistically significantly higher mean levels of IGF-I than control subjects (229 ng/mL; 95% confidence interval [CT] = 218-240 ng/mL] versus 214 ng/mL [95% CI = 208-221 ng/mL]; P = .02) and IGFBP-3 (2611 ng/mL [95% CI = 2518-2704 ng/mL] versus 2498 ng/mL [95% CI = 2437-2560 ng/mL]; P = .04). Conditional logistic regression analyses showed increases in prostate cancer risk with rising levels of IGF-I (P-for trend = .02) and IGFBP-3 (P-for trend = .03). In case subjects younger than 59 years at the time of blood collection, the risk associated with increased IGF-I was higher (P-for trend = .01), whereas the risk associated with increased IGFBP-3 was lower (P-for trend = .44) than the corresponding risks in the full cohort. Prostate cancer risk was not associated with levels of IGFBP-1, IGFBP-2, or insulin. Conclusions: Prostate cancer risk is increased in men with elevated plasma IGF-I, This association was particularly strong in younger men in this study, suggesting that circulating IGF-I mag be specifically involved in the early pathogenesis of prostate cancer.